1. Home
  2.  » 
  3. Solutions
  4.  » Brexit Solutions for the UK & EU

Catalent Clinical Supply Solutions for a Post-Brexit Europe

Minimize Risks to Continuity of Supply in European and UK Studies Posed by the New Brexit Deal

Following the UK vote to leave the EU in 2016, Catalent has worked diligently, alongside our customers, to ensure that we were prepared to maintain continuity of clinical supply to patients across Europe following Brexit, regardless of the outcome.

As a result, Catalent’s Brexit Team is ready to help sponsors understand the trade, regulatory and related implications of the new Brexit deal for clinical supply chains and can deploy a series of comprehensive, yet flexible solutions to help sponsors maintain uninterrupted supply to patients moving forward. Furthermore, Catalent’s turnkey Brexit solutions help ensure minimal disruption to established clinical supply chains, while potentially saving sponsors energy, time and cost in comparison to alternative Brexit risk mitigation options.

CATALENT CLINICAL SUPPLY SERVICES OFFERS SPONSORS MITIGATING THE IMPACT OF BREXIT:

  • Access to industry-leading experts from our Brexit Strategic Planning Team to best support your risk mitigation activities
  • A global network of GMP clinical supply facilities, including sites which have been established and working together in the UK (GB) and EU for 20+ years, to support clinical supply chains across Europe and worldwide
  • Brexit solutions that can produce efficiencies in mitigating the risk to clinical supply chain continuity
  • A full range of comprehensive clinical supply services, available through our UK (GB) and EU sites
If you are a sponsor, consultant or CRO with existing or planned clinical trials in Europe, and would like to find out how Catalent can help you ensure that your clinical supply chain is Brexit-ready, learn more below and contact us to speak to one of our experts about Brexit: